On April 27, 2017 STRATA Skin Sciences, Inc. (the “Company”) announced the introduction of the Nordlys device at the American Society for Lasers in Medicine and Surgery meeting in San Diego, CA and the Company’s forecasted revenue and EBITDA contributions for 2017 sales of Nordlys systems.

In connection with this event, the Company issued a press release, a copy of which is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

Exhibit No. Exhibit Description

99.1 Press Release dated April 27, 2017

About STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN)

STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company’s technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment.

STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) Recent Trading Information

STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) closed its last trading session down -0.46 at 3.40 with 2,181,151 shares trading hands.